source
- FDA releases draft PDUFA VIII commitment letter outlining goals and enhancements for 2028-2032The FDA on Thursday issued a proposed commitment letter for the upcoming PDUFA VIII cycle, which will cover fiscal years 2028 through 2032. The letter sets out the agency's performance targets for…
- Former Legend Biotech CEO Ying Huang appointed head of K2 TherapeuticsK2 Therapeutics announced that Ying Huang, who recently left his role as CEO of Legend Biotech, will now lead the young biotech company. The appointment comes just weeks after Legend announced Huan…